Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsMIL:1CORT 62 EV-to-EBIT is 1,911.92 as of Aug. 03, 2026, which is 8555% above its 10-year median of 22.09. GuruFocus rates MIL:1CORT with a GF Score™ of 62/100 and a GF Value™ of €59.26 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 387 Biotechnology companies, Corcept Therapeutics ranks worse than 99.74% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Corcept Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was €8,070.0 Mil.
Corcept Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics EV-to-EBIT Related Terms
Corcept Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1CORT vs APGE, KRYS, NUVL: EV-to-EBIT Comparison
For the Biotechnology subindustry, Corcept Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's EV-to-EBIT falls into.
Corcept Therapeutics's current Enterprise Value is €10,481.1 Mil.
Corcept Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (MIL:1CORT) has a EV-to-EBIT of 1,911.92 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Corcept Therapeutics and its competitors. This is 8555% above median its historical median of 22.09. According to the industry distribution chart, Corcept Therapeutics ranks #386 out of 387 companies in the Biotechnology industry, placing it in the top 99.7%.
Is Corcept Therapeutics' EV-to-EBIT too high?
Corcept Therapeutics' current EV-to-EBIT of 1,911.92 is 8555% above median its 10-year median of 22.09. The Biotechnology industry median EV-to-EBIT is 12.63. Corcept Therapeutics' value of 1,911.92 is 15037.9% above this industry median. Based on the distribution chart, Corcept Therapeutics ranks #386 out of 387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' EV-to-EBIT compare to APGE and KRYS?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #386 out of 387 companies for EV-to-EBIT. This places Corcept Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 12.63. Corcept Therapeutics' value of 1,911.92 is 15037.9% above this benchmark. While the company's 10-year median is 22.09 vs. the industry median of 12.63, Corcept Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.63, based on 387 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current EV-to-EBIT of 1,911.92 is 15037.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current EV-to-EBIT is 1,911.92, which is 8555% above median its own 10-year median of 22.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (MIL:1CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is €59.26, compared to a current price of €104.80 — trading 76.8% above its estimated fair value. The current EV-to-EBIT is 1,911.92, which is 8555% above median its 10-year median of 22.09 and 15037.9% above the Biotechnology industry median of 12.63. Corcept Therapeutics' overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Corcept Therapeutics (MIL:1CORT), the current EV-to-EBIT is 1,911.92 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (MIL:1CORT) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €104.80 is trading 76.8% above its estimated GF Value™ of €59.26.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for MIL:1CORT:
EV-to-EBIT: 1,911.92 (8555% above median its 10-year median of 22.09)
GF Value™: €59.26 vs. price of €104.80 (76.8% above fair value)
Industry Position: 15037.9% above the Biotechnology median (#386 of 387)
No single metric tells the full story. See the MIL:1CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
62GF Score
Get the complete analysis for MIL:1CORT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1CORT has been successfully added to your 
